Display options
Cite
Trovato FM, Tognarelli JM, Crossey MM, et al. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J Hepatol. 2015;7(26):2664-75doi: 10.4254/wjh.v7.i26.2664.
Trovato, F. M., Tognarelli, J. M., Crossey, M. M., Catalano, D., Taylor-Robinson, S. D., & Trovato, G. M. (2015). Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World journal of hepatology, 7(26), 2664-75. https://doi.org/10.4254/wjh.v7.i26.2664
Trovato, Francesca M, et al. "Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers." World journal of hepatology vol. 7,26 (2015): 2664-75. doi: https://doi.org/10.4254/wjh.v7.i26.2664
Trovato FM, Tognarelli JM, Crossey MM, Catalano D, Taylor-Robinson SD, Trovato GM. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J Hepatol. 2015 Nov 18;7(26):2664-75. doi: 10.4254/wjh.v7.i26.2664. PMID: 26609343; PMCID: PMC4651910.
Copy Download .nbib Format: NLM
Share it on

World J Hepatol. 2015 Nov 18;7(26):2664-75. doi: 10.4254/wjh.v7.i26.2664.

Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers.

World journal of hepatology

Francesca M Trovato, Joshua M Tognarelli, Mary Me Crossey, Daniela Catalano, Simon D Taylor-Robinson, Guglielmo M Trovato

Affiliations

  1. Francesca M Trovato, Daniela Catalano, Guglielmo M Trovato, Dipartimento di Medicina Clinica e Sperimentale, Scuola di Medicina, Università di Catania, 95100 Catania, Italy.

PMID: 26609343 PMCID: PMC4651910 DOI: 10.4254/wjh.v7.i26.2664

Abstract

Chronic liver disease has become a global health problem as a result of the increasing incidence of viral hepatitis, obesity and alcohol misuse. Over the past three decades, in the United Kingdom alone, deaths from chronic liver disease have increased both in men and in women. Currently, 2.5% of deaths worldwide are attributed to liver disease and projected figures suggest a doubling in hospitalisation and associated mortality by 2020. Chronic liver diseases vary for clinical manifestations and natural history, with some individuals having relatively indolent disease and others with a rapidly progressive course. About 30% of patients affected by hepatitis C has a progressive disease and develop cirrhosis over a 20 years period from the infection, usually 5-10 years after initial medical presentation. The aim of the current therapeutic strategies is preventing the progression from hepatitis to fibrosis and subsequently, cirrhosis. Hepatic steatosis is a risk factor for chronic liver disease and is affecting about the half of patients who abuse alcohol. Moreover non-alcoholic fatty liver disease is part of the metabolic syndrome, associated with obesity, hypertension, type II diabetes mellitus and dyslipidaemia, and a subgroup of patients develops non-alcoholic steatohepatitis and fibrosis with subsequent cirrhosis. The strengths and pitfalls of liver biopsy are discussed and a variety of new techniques to assess liver damage from transient elastography to experimental techniques, such as in vitro urinary nuclear magnetic resonance spectroscopy. Some of the techniques and tests described are already suitable for more widespread clinical application, as is the case with ultrasound-based liver diagnostics, but others, such as urinary metabonomics, requires a period of critical evaluation or development to take them from the research arena to clinical practice.

Keywords: Fibrosis; Liver cancer; Ultrasound; Urinary biomarkers; Virus hepatitis

References

  1. Hepatology. 2014 Jul;60(1):15-8 - PubMed
  2. J Gastroenterol Hepatol. 2004 Mar;19(3):327-32 - PubMed
  3. Diagn Pathol. 2014;9 Suppl 1:S2 - PubMed
  4. Hepatology. 1991 Jun;13(6):1112-6 - PubMed
  5. J Proteome Res. 2012 Feb 3;11(2):717-27 - PubMed
  6. Cancer Res. 1976 May;36(5):1714-6 - PubMed
  7. World J Nephrol. 2015 Feb 6;4(1):127-37 - PubMed
  8. Dig Dis. 2011;29(1):93-7 - PubMed
  9. J Hepatol. 2012 Apr;56(4):848-54 - PubMed
  10. BMC Med Ethics. 2015 May 28;16:36 - PubMed
  11. Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6 - PubMed
  12. J Hepatol. 1995 Jun;22(6):696-9 - PubMed
  13. J Proteome Res. 2011 Apr 1;10(4):1828-36 - PubMed
  14. EPMA J. 2014 Aug 27;5(1):14 - PubMed
  15. Nature. 2008 Oct 23;455(7216):1054-6 - PubMed
  16. Sci Rep. 2015 May 12;5:9954 - PubMed
  17. Evid Based Med. 2015 Apr;20(2):59 - PubMed
  18. World J Gastroenterol. 2014 Feb 14;20(6):1544-53 - PubMed
  19. Hepatology. 2012 Sep;56(3):793-6 - PubMed
  20. Hepatology. 2003 Apr;37(4):788-94 - PubMed
  21. Cancer Res. 1974 May;34(5):986-90 - PubMed
  22. Diagn Pathol. 2008 Jul 15;3 Suppl 1:S2 - PubMed
  23. N Engl J Med. 2002 Apr 18;346(16):1221-31 - PubMed
  24. Gut. 2005 Jan;54(1):128-33 - PubMed
  25. Gastroenterology. 2008 May;134(6):1670-81 - PubMed
  26. BMJ. 1999 Sep 4;319(7210):640 - PubMed
  27. Gut. 2005 Jan;54(1):122-7 - PubMed
  28. World J Gastroenterol. 2014 Oct 28;20(40):14706-16 - PubMed
  29. Clin Nutr. 2015 Feb;34(1):86-8 - PubMed
  30. Clin Gastroenterol Hepatol. 2014 Nov;12(11):1927-33.e2 - PubMed
  31. Am Fam Physician. 2005 Mar 15;71(6):1153-62 - PubMed
  32. Int J Biol Markers. 1998 Apr-Jun;13(2):92-7 - PubMed
  33. Eur J Clin Chem Clin Biochem. 1993 Apr;31(4):205-9 - PubMed
  34. Dig Dis. 2014;32(5):545-53 - PubMed
  35. N Engl J Med. 1978 Oct 26;299(17):926-30 - PubMed
  36. Eur Rev Med Pharmacol Sci. 2014;18(2):151-9 - PubMed
  37. J Hepatol. 2014 Aug;61(2):333-41 - PubMed
  38. Cancer Epidemiol. 2012 Apr;36(2):e89-94 - PubMed
  39. Anal Chim Acta. 2009 Aug 19;648(1):98-104 - PubMed
  40. Clin Gastroenterol Hepatol. 2007 Oct;5(10 ):1207-1213.e2 - PubMed
  41. Hepatology. 2003 Dec;38(6):1449-57 - PubMed
  42. Expert Rev Gastroenterol Hepatol. 2009 Aug;3(4):353-67 - PubMed
  43. Hepatology. 2011 Dec;54(6):2055-63 - PubMed
  44. Dig Dis Sci. 1991 Jul;36(7):962-72 - PubMed
  45. Lancet. 1997 Oct 18;350(9085):1142-3 - PubMed
  46. Cancer. 1981 Jan 1;47(1):113-8 - PubMed
  47. Ann Surg Oncol. 2009 Oct;16(10 ):2805-17 - PubMed
  48. J Proteome Res. 2010 Feb 5;9(2):1096-103 - PubMed
  49. Hepatology. 2014 Oct;60(4):1291-301 - PubMed
  50. Gastroenterology. 2008 Apr;134(4):960-74 - PubMed
  51. Hepatology. 2013 Dec;58(6):2142-52 - PubMed
  52. Hepatology. 2008 Jan;47(1):332-42 - PubMed
  53. Biochem Biophys Res Commun. 1990 Mar 30;167(3):1065-72 - PubMed
  54. World J Hepatol. 2015 May 28;7(9):1157-67 - PubMed
  55. Am J Gastroenterol. 1992 Apr;87(4):471-6 - PubMed
  56. Liver Int. 2008 Nov;28(9):1280-7 - PubMed
  57. Cancer Lett. 2010 Jan 1;287(1):13-22 - PubMed
  58. Br J Cancer. 1997;75(10):1460-6 - PubMed
  59. Tohoku J Exp Med. 1988 Aug;155(4):311-8 - PubMed
  60. Cancer. 1986 Apr 15;57(8):1571-5 - PubMed
  61. Lancet. 2005 Oct 8;366(9493):1303-14 - PubMed
  62. EPMA J. 2014 Dec 07;5(1):21 - PubMed
  63. Arch Pathol Lab Med. 2011 Feb;135(2):215-9 - PubMed
  64. Hepatology. 2007 Sep;46(3):658-65 - PubMed
  65. Dig Liver Dis. 2014 Jun;46(6):549-55 - PubMed
  66. Rapid Commun Mass Spectrom. 2009 Jun;23(11):1543-9 - PubMed
  67. Gut. 2012 Dec;61(12 ):1657-69 - PubMed
  68. J Hepatol. 2015 Jul;63(1):237-64 - PubMed

Publication Types

Grant support